MOESM1 of Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo
figureposted on 12.12.2017, 05:00 by Ditte Reker, Cecilie Kjelgaard-Petersen, Anne Siebuhr, Martin Michaelis, Anne Gigout, Morten Karsdal, Christoph Ladel, Anne Bay-Jensen
Additional file 1. Aggrecan formation in bovine cartilage explants. Bovine cartilage explants were pre-cultured for 1 week, and then cultured for further 5 weeks with weekly administration (48 hÂ duration) of indicated compounds. CS846 (IBEX Pharmaceuticals Inc.) was measured in conditioned media collected at 1, 3 and 5 weeks of compound-culturing. Values were placebo-corrected and all data presented as means Âą SEM of six replicate explants. One-way ANOVA was used for multiple comparisons to the placebo group at each time point. Significance levels are indicated by asterisks; *P < 0.05, **P < 0.01, ***P < 0.001. All results are from one study (Study 2).